Thomas Jefferson University

Walter Kraft

TitleFaculty Physician
InstitutionThomas Jefferson University
DepartmentPharmacology/Experimental Therapeutics - Thomas Jefferson University
Address1020 Sansom Street
Philadelphia PA 19107
Phone2159559077
vCardDownload vCard

    Collapse Biography 
    Collapse awards and honors
    2010Early Career Investigator Award for Distinguished Achievement in Biomedical Research, Jefferson Medical College
    2014Dean's Award for Excellence in Education, Jefferson Medical College

    Collapse Research 
    Collapse research activities and funding
    T32GM008562     (KRAFT, WALTER K)Jul 1, 1995 - Jun 30, 2030
    NIH
    Clinical Pharmacology Training Program
    Role: Co-Principal Investigator
    R21DA018207     (KRAFT, WALTER K.)Sep 1, 2005 - Aug 31, 2009
    NIH
    Buprenorphine Treatment of Neonatal Abstinence Syndrome
    Role: Principal Investigator
    R01DA029076     (KRAFT, WALTER K)Jun 1, 2011 - Apr 30, 2019
    NIH
    A Comparison of Buprenorphine Versus Morphine in the Treatment of the Neonatal Ab
    Role: Principal Investigator
    UG1HD107628     (KRAFT, WALTER K)Sep 17, 2021 - Aug 31, 2026
    NIH
    Thomas Jefferson University Hospital Clinical Site for HEAL NOWS Pharmacologic Trial
    Role: Principal Investigator
    T32HD117733     (KRAFT, WALTER K)May 21, 2025 - Apr 30, 2030
    NIH
    Clinical Pharmacology Training Program
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kraft WK. Optimal Drug, Optimal Dose, or Both in the Pharmacological Treatment of Neonatal Opioid Withdrawal Syndrome? Clin Pharmacol Ther. 2025 May; 117(5):1182-1184. PMID: 39935314.
      Citations:    
    2. Lam K, Peltz G, Kraft WK. The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets. Expert Opin Investig Drugs. 2025 Jan-Feb; 34(1-2):49-59. PMID: 39900407.
      Citations:    
    3. Lam K, Mondick JT, Peltz G, Wu M, Kraft WK. Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome. Clin Transl Sci. 2025 Feb; 18(2):e70147. PMID: 39930952.
      Citations:    
    4. Tichauer KM, Machado P, Liu JB, Sarathchandra ASC, Stanczak M, Kraft WK, Forsberg F. Macrophage uptake rate of Sonazoid in breast lymphosonography is highly conserved in healthy controls. Phys Med Biol. 2024 Oct 04; 69(20). PMID: 39317237.
      Citations:    
    5. Riley C, Kraft WK, Miller R. Hydroxyurea in the sickle cell disease modern era. Expert Rev Clin Pharmacol. 2024 Sep; 17(9):777-791. PMID: 39135533.
      Citations:    
    6. Zang X, Ankrom W, Kraft WK, Vargo R, Stoch SA, Iwamoto M, Matthews RP. Intracellular islatravir-triphosphate half-life supports extended dosing intervals. Antimicrob Agents Chemother. 2024 09 04; 68(9):e0045824. PMID: 39105584.
      Citations:    
    7. Anbalagan S, Anderson V, Favara MT, Stark D, Carola D, Solarin K, Adeniyi-Jones S, Kraft WK, Aghai ZH. Buprenorphine vs. morphine: impact on neonatal opioid withdrawal syndrome (NOWS) outcomes in a single center retrospective study. J Perinatol. 2025 Apr; 45(4):473-479. PMID: 39003405.
      Citations:    
    8. Boelig RC, Lam K, Rochani A, Soni V, Kaushal G, Kraft WK. Azithromycin dosing and preterm premature rupture of membranes treatment (ADAPT): a randomized controlled Phase I trial. Am J Obstet Gynecol MFM. 2024 Sep; 6(9):101423. PMID: 38977063.
      Citations:    
    9. Zheng R, Lam E, Altshuler P, Crutcher M, Lavu H, Yeo CJ, Stickle D, Leiby B, Kraft WK. Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP). Int J Clin Pharmacol Ther. 2024 Jul; 62(7):319-325. PMID: 38660886.
      Citations:    
    10. Lam K, Kraft WK, Zhan T, Lam E. Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial. Clin Transl Sci. 2024 03; 17(3):e13721. PMID: 38421210.
      Citations:    
    11. Maisel BA, Adeniyi-Jones SC, Selvage E, Ng S, Kraft WK, Chervoneva I. Abstinence scoring algorithms for treatment of neonatal opioid withdrawal syndrome (NOWS). J Perinatol. 2024 Aug; 44(8):1132-1136. PMID: 38366118.
      Citations:    
    12. Kraft WK, Barneschi I, Bocchi M, Santoro D, Cella M. The Bioavailability of CHF6563, an Ethanol-Free, Sublingual Neonatal Buprenorphine Formulation: A Bridging Study Conducted in Adults. J Pediatr Pharmacol Ther. 2024; 29(1):49-52. PMID: 38332965.
      Citations:    
    13. Boelig RC, Kaushal G, Rochani A, McKenzie SE, Kraft WK. Aspirin pharmacokinetics and pharmacodynamics through gestation. Am J Obstet Gynecol. 2024 Sep; 231(3):344.e1-344.e16. PMID: 38145726.
      Citations:    
    14. Peltz G, Jansson LM, Adeniyi-Jones S, Cohane C, Drover D, Shafer S, Wang M, Wu M, Govindaswami B, Jegatheesan P, Argani C, Khan S, Kraft WK. Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial. J Perinatol. 2023 03; 43(3):271-276. PMID: 36030327.
      Citations:    
    15. Bibi S, Gaddis N, Johnson EO, Lester BM, Kraft W, Singh R, Terrin N, Adeniyi-Jones S, Davis JM. Polygenic risk scores and the need for pharmacotherapy in neonatal abstinence syndrome. Pediatr Res. 2023 04; 93(5):1368-1374. PMID: 35974158.
      Citations:    
    16. Boelig RC, Cahanap TJ, Ma L, Zhan T, Berghella V, Chan JSY, Kraft WK, Mckenzie SE. Platelet protease activated receptor 4 (PAR 4) receptor genotype is associated with an increased risk of preterm birth. J Thromb Haemost. 2022 10; 20(10):2419-2428. PMID: 35815338.
      Citations:    
    17. Kraft WK. Clinical Pharmacology and the Best Use of Public Research Investment. Clin Pharmacol Ther. 2022 06; 111(6):1185-1188. PMID: 35586960.
      Citations:    
    18. Mansell H, Shoker A, Alcorn J, Fenton ME, Tam JS, Semchuk W, Bashir B, Kraft WK, Yao S, Douketis JD. Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients. Clin Transl Sci. 2022 07; 15(7):1687-1697. PMID: 35439353.
      Citations:    
    19. Merli GJ, Kraft WK, Eraso LH, Galanis T, Thomson LJ, Ouma GO, Viscusi E, Gong JZ, Lam E. Apixaban Discontinuation for Invasive Or major Surgical procedures (ADIOS): A prospective cohort study. Vasc Med. 2022 06; 27(3):269-276. PMID: 34809507.
      Citations:    
    20. Lam E, Ting Kayla Lien Y, Kraft WK, Stickle DF, Piraino B, Zhang J. Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis. Clin Transl Sci. 2022 03; 15(3):649-657. PMID: 34755479.
      Citations:    
    21. Weinberg DS, Foster NR, Della'Zanna G, McMurray RP, Kraft WK, Pallotto A, Kastenberg DM, Katz LC, Henry CH, Moleski SM, Limburg PJ, Waldman SA. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biol Ther. 2021 12 02; 22(10-12):544-553. PMID: 34632925.
      Citations:    
    22. Liles DK, Shah NR, Scullin B, Gordeuk VR, Smith WR, Kanter J, Achebe MM, Boccia R, Crary SE, Kraft WK, Archer N, Cataldo V, Hardesty BM, Idowu M, Desai PC, Ikeda A, Puthenveetil G, Hassell KL, Sarnaik S, Kutlar A. Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study. Br J Haematol. 2021 11; 195(4):e150-e153. PMID: 34611900.
      Citations:    
    23. Devlin LA, Young LW, Kraft WK, Wachman EM, Czynski A, Merhar SL, Winhusen T, Jones HE, Poindexter BB, Wakschlag LS, Salisbury AL, Matthews AG, Davis JM. Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants. J Perinatol. 2022 Mar; 42(3):300-306. PMID: 34556799.
      Citations:    
    24. Eudy-Byrne R, Zane N, Adeniyi-Jones SC, Gastonguay MR, Ruiz-Garcia A, Kaushal G, Kraft WK. Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome. Clin Transl Sci. 2021 11; 14(6):2171-2183. PMID: 34080312.
      Citations:    
    25. Boelig RC, Lam E, Rochani A, Kaushal G, Roman A, Kraft WK. Longitudinal evaluation of azithromycin and cytokine concentrations in amniotic fluid following one-time oral dosing in pregnancy. Clin Transl Sci. 2021 11; 14(6):2431-2439. PMID: 34310083.
      Citations:    
    26. Becker ML, Kraft WK. Seeking Similarities Rather Than Differences With Adults to Aid in Therapeutic Advancement for Children. Clin Pharmacol Ther. 2021 07; 110(1):11-14. PMID: 34148235.
      Citations:    
    27. Rochani A, Nguyen V, Becker R, Kraft W, Kaushal G. Stability-indicating LC-MS Method for Determination of Stability of Extemporaneously Compounded Buprenorphine Oral Syringes for Neonatal Abstinence Syndrome. J Pediatr Pharmacol Ther. 2021; 26(4):395-404. PMID: 34035685.
      Citations:    
    28. Smith J, Lafferty M, Boelig RC, Carola D, Adeniyi-Jones S, Kraft WK, Greenspan JS, Aghai ZH. Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome? Am J Perinatol. 2022 07; 39(10):1138-1144. PMID: 33321531.
      Citations:    
    29. Min KC, Kraft WK, Bondiskey P, Col?n-Gonz?lez F, Liu W, Xu J, Panebianco D, Mixson L, Dockendorf MF, Matthews CZ, Boinpally R. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults. Clin Transl Sci. 2021 03; 14(2):599-605. PMID: 33142014.
      Citations:    
    30. Lam E, Schaefer J, Zheng R, Zhan T, Kraft WK. Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers. Clin Transl Sci. 2020 11; 13(6):1244-1250. PMID: 32407548.
      Citations:    
    31. Chervoneva I, Adeniyi-Jones SC, Blanco F, Kraft WK. Development of an abbreviated symptom score for the neonatal abstinence syndrome. J Perinatol. 2020 07; 40(7):1031-1040. PMID: 32076111.
      Citations:    
    32. Ankrom W, Bondiskey P, Li CC, Palcza J, Liu W, Dockendorf MF, Matthews C, Panebianco D, Reynders T, Wagner JA, Jakate A, Mesens S, Kraft WK, Marcantonio EE. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males. Clin Transl Sci. 2020 05; 13(3):462-472. PMID: 31899602.
      Citations:    
    33. Rochani A, Lam E, Tanjuakio J, Hirose H, Kraft WK, Kaushal G. Simultaneous quantitative LC-MS method of ketamine, midazolam and their metabolites (dehydronorketamine, norketamine and 1hydroxymidazolam) for its application in patients on extracorporeal membrane oxygenation (ECMO) therapy. J Pharm Biomed Anal. 2020 Jan 30; 178:112947. PMID: 31708269.
      Citations:    
    34. Lam E, Bashir B, Chaballa M, Kraft WK. Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy. Expert Rev Clin Pharmacol. 2019 Aug; 12(8):781-790. PMID: 31242782.
      Citations:    
    35. Boelig RC, Zuppa AF, Kraft WK, Caritis S. Pharmacokinetics of vaginal progesterone in pregnancy. Am J Obstet Gynecol. 2019 09; 221(3):263.e1-263.e7. PMID: 31211965.
      Citations:    
    36. Liu T, Lewis TR, Moore JN, Kraft WK, Gauda EB, Sartori D, Moody DE, Gobburu JVS, Ivaturi V. Could Postnatal Age-Related Uridine Diphosphate Glucuronic Acid Be a Rate-Limiting Factor in the Metabolism of Morphine During the First Week of Life? CPT Pharmacometrics Syst Pharmacol. 2019 07; 8(7):469-477. PMID: 31044547.
      Citations:    
    37. Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. Clin Drug Investig. 2019 May; 39(5):441-451. PMID: 30810914.
      Citations:    
    38. Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK. Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. Clin Drug Investig. 2019 May; 39(5):453-454. PMID: 30895461.
      Citations:    
    39. Snook AE, Baybutt TR, Xiang B, Abraham TS, Flickinger JC, Hyslop T, Zhan T, Kraft WK, Sato T, Waldman SA. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Cancer. 2019 04 23; 7(1):104. PMID: 31010434.
      Citations:    
    40. McCrea JB, Macha S, Adedoyin A, Marshall W, Menzel K, Cho CR, Liu F, Zhao T, Levine V, Kraft WK, Yoon E, Panebianco D, Stoch SA, Iwamoto M. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil. J Clin Pharmacol. 2019 10; 59(10):1331-1339. PMID: 30990905.
      Citations:    
    41. Jones HE, Kraft WK. Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. Clin Perinatol. 2019 06; 46(2):349-366. PMID: 31010564.
      Citations:    
    42. Mangat AK, Schm?lzer GM, Kraft WK. Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS). Semin Fetal Neonatal Med. 2019 04; 24(2):133-141. PMID: 30745219.
      Citations:    
    43. Anderson MS, Gilmartin J, Fan L, Yee KL, Kraft WK, Triantafyllou I, Reitmann C, Guo Y, Liu R, Iwamoto M. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration. Antivir Ther. 2019; 24(6):443-450. PMID: 31433304.
      Citations:    
    44. Bashir B, Stickle DF, Chervoneva I, Kraft WK. Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers. Clin Transl Sci. 2018 11; 11(6):590-596. PMID: 29972633.
      Citations:    
    45. Davis JJ, Price DW, Kraft W, Lane-Fall MB. Incorporation of Quality and Safety Principles in Maintenance of Certification: A Qualitative Analysis of American Board of Medical Specialties Member Boards. Am J Med Qual. 2019 Mar/Apr; 34(2):176-181. PMID: 29973059.
      Citations:    
    46. Moore JN, Gastonguay MR, Ng CM, Adeniyi-Jones SC, Moody DE, Fang WB, Ehrlich ME, Kraft WK. The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome. Clin Pharmacol Ther. 2018 06; 103(6):1029-1037. PMID: 29516490.
      Citations:    
    47. Marbach JA, Johnson D, Kloo J, Vira A, Keith S, Kraft WK, Margules N, Whellan D. The Impact of a Transition of Care Program on Acute Myocardial Infarction Readmission Rates. Am J Med Qual. 2018 Sep/Oct; 33(5):481-486. PMID: 29374965.
      Citations:    
    48. Elia J, Ungal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larsen L, Chiavacci R, Wang T, Kurian C, Titchen K, Sykes B, Hwang S, Kumar B, Potts J, Davis J, Malatack J, Slattery E, Moorthy G, Zuppa A, Weller A, Byrne E, Li YR, Kraft WK, Hakonarson H. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Nat Commun. 2018 01 16; 9(1):4. PMID: 29339723.
      Citations:    
    49. Machado P, Stanczak M, Liu JB, Moore JN, Eisenbrey JR, Needleman L, Kraft WK, Forsberg F. Subdermal Ultrasound Contrast Agent Injection for Sentinel Lymph Node Identification: An Analysis of Safety and Contrast Agent Dose in Healthy Volunteers. J Ultrasound Med. 2018 Jul; 37(7):1611-1620. PMID: 29205451.
      Citations:    
    50. Kraft WK. Buprenorphine in Neonatal Abstinence Syndrome. Clin Pharmacol Ther. 2018 Jan; 103(1):112-119. PMID: 29105752.
      Citations:    
    51. Shah AG, Peahota M, Thoma BN, Kraft WK. Medication Complications in Extracorporeal Membrane Oxygenation. Crit Care Clin. 2017 Oct; 33(4):897-920. PMID: 28887935.
      Citations:    
    52. Kraft WK, Adeniyi-Jones SC, Ehrlich ME. Buprenorphine for the Neonatal Abstinence Syndrome. N Engl J Med. 2017 09 07; 377(10):997-998. PMID: 28877016.
      Citations:    
    53. Filippone EJ, Kraft WK, Farber JL. The Nephrotoxicity of Vancomycin. Clin Pharmacol Ther. 2017 Sep; 102(3):459-469. PMID: 28474732.
      Citations:    
    54. Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol. 2017 Aug; 10(8):899-910. PMID: 28490202.
      Citations:    
    55. Kraft WK, Adeniyi-Jones SC, Chervoneva I, Greenspan JS, Abatemarco D, Kaltenbach K, Ehrlich ME. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. N Engl J Med. 2017 06 15; 376(24):2341-2348. PMID: 28468518.
      Citations:    
    56. Weinberg DS, Lin JE, Foster NR, Della'Zanna G, Umar A, Seisler D, Kraft WK, Kastenberg DM, Katz LC, Limburg PJ, Waldman SA. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Jun; 10(6):345-354. PMID: 28396341.
      Citations:    
    57. Moore JN, Healy JR, Thoma BN, Peahota MM, Ahamadi M, Schmidt L, Cavarocchi NC, Kraft WK. A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy. CPT Pharmacometrics Syst Pharmacol. 2016 09; 5(9):495-502. PMID: 27639260.
      Citations:    
    58. Kraft WK, Gilmartin JH, Chappell DL, Gheyas F, Walker BM, Nagalla S, Naik UP, Horrow JC, Wrishko RE, Zhang S, Anderson MS. Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects. Clin Transl Sci. 2016 08; 9(4):221-7. PMID: 27304196.
      Citations:    
    59. Nagalla S, Thomson L, Oppong Y, Bachman B, Chervoneva I, Kraft WK. Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers. Clin Transl Sci. 2016 06; 9(3):176-80. PMID: 27170068.
      Citations:    
    60. Chalouhi N, Daou B, Okabe T, Starke RM, Dalyai R, Bovenzi CD, Anderson EC, Barros G, Reese A, Jabbour P, Tjoumakaris S, Rosenwasser R, Kraft WK, Rincon F. Beta-blocker therapy and impact on outcome after aneurysmal subarachnoid hemorrhage: a cohort study. J Neurosurg. 2016 09; 125(3):730-6. PMID: 26799296.
      Citations:    
    61. Kraft WK, Stover MW, Davis JM. Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant. Semin Perinatol. 2016 Apr; 40(3):203-12. PMID: 26791055.
      Citations:    
    62. Gaballa S, Palmisiano N, Alpdogan O, Carabasi M, Filicko-O'Hara J, Kasner M, Kraft WK, Leiby B, Martinez-Outschoorn U, O'Hara W, Pro B, Rudolph S, Sharma M, Wagner JL, Weiss M, Flomenberg N, Grosso D. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell?Transplantation. Biol Blood Marrow Transplant. 2016 Jan; 22(1):141-8. PMID: 26415558.
      Citations:    
    63. Ng CM, Dombrowsky E, Lin H, Erlich ME, Moody DE, Barrett JS, Kraft WK. Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. Pharmacotherapy. 2015 Jul; 35(7):670-80. PMID: 26172282.
      Citations:    
    64. Moore JN, Healy JR, Kraft WK. Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol. 2015 May; 8(3):321-34. PMID: 25916666.
      Citations:    
    65. van den Anker JN, Allegaert K, Kraft WK. Current Therapeutic Research is Now Indexed on PubMed. Curr Ther Res Clin Exp. 2014 Dec; 76:98. PMID: 25389447.
      Citations:    
    66. Marek E, Kraft WK. Ethanol pharmacokinetics in neonates and infants. Curr Ther Res Clin Exp. 2014 Dec; 76:90-7. PMID: 25379066.
      Citations:    
    67. Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014 Jul; 58(7):4020-5. PMID: 24798274.
      Citations:    
    68. Vaid U, Singer E, Marhefka GD, Kraft WK, Baram M. Poor positive predictive value of McConnell's sign on transthoracic echocardiography for the diagnosis of acute pulmonary embolism. Hosp Pract (1995). 2013 Aug; 41(3):23-7. PMID: 23948618.
      Citations:    
    69. Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Res. 2013 Sep; 99(3):214-20. PMID: 23747481.
      Citations:    
    70. Okabe T, Kanzaria M, Rincon F, Kraft WK. Cardiovascular protection to improve clinical outcomes after subarachnoid hemorrhage: is there a proven role? Neurocrit Care. 2013 Apr; 18(2):271-84. PMID: 23238984.
      Citations:    
    71. Halegoua-De Marzio D, Kraft WK, Daskalakis C, Ying X, Hawke RL, Navarro VJ. Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract. Clin Ther. 2012 Dec; 34(12):2279-2285.e1. PMID: 23153661.
      Citations:    
    72. Pavri BB, Greenberg HE, Kraft WK, Lazarus N, Lynch JJ, Salata JJ, Bilodeau MT, Regan CP, Stump G, Fan L, Mehta A, Wagner JA, Gutstein DE, Bloomfield D. MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans. Circ Arrhythm Electrophysiol. 2012 Dec; 5(6):1193-201. PMID: 23060423.
      Citations:    
    73. Kraft WK, van den Anker JN. Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatr Clin North Am. 2012 Oct; 59(5):1147-65. PMID: 23036249.
      Citations:    
    74. Kupetsky-Rincon EA, Kraft WK. Healthy volunteer registries and ethical research principles. Clin Pharmacol Ther. 2012 Jun; 91(6):965-8. PMID: 22609908.
      Citations:    
    75. Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA, Iwamoto M. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus. Cancer Chemother Pharmacol. 2012 May; 69(5):1247-53. PMID: 22290273.
      Citations:    
    76. Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol. 2012 Jul; 68(7):1049-56. PMID: 22315147.
      Citations:    
    77. Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, Persson A, Huang SP, Hernandez D, Sheaffer AK, Scola P, Marbury T, Lawitz E, Goldwater R, Rodriguez-Torres M, Demicco M, Wright D, Charlton M, Kraft WK, Lopez-Talavera JC, Grasela DM. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr; 56(4):1838-44. PMID: 22290978.
      Citations:    
    78. Cavallazzi R, Awe OO, Vasu TS, Hirani A, Vaid U, Leiby BE, Kraft WK, Kane GC. Model for End-Stage Liver Disease score for predicting outcome in critically ill medical patients with liver cirrhosis. J Crit Care. 2012 Aug; 27(4):424.e1-6. PMID: 22227088.
      Citations:    
    79. Reitman ML, Dishy V, Moreau A, Denney WS, Liu C, Kraft WK, Mejia AV, Matson MA, Stoch SA, Wagner JA, Lai E. Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients. J Clin Pharmacol. 2012 Sep; 52(9):1306-16. PMID: 22162541.
      Citations:    
    80. Anagnostis EA, Sadaka RE, Sailor LA, Moody DE, Dysart KC, Kraft WK. Formulation of buprenorphine for sublingual use in neonates. J Pediatr Pharmacol Ther. 2011 Oct; 16(4):281-4. PMID: 22768012.
      Citations:    
    81. Henwood PC, Kennedy TM, Thomson L, Galanis T, Tzanis GL, Merli GJ, Kraft WK. The incidence of deep vein thrombosis detected by routine surveillance ultrasound in neurosurgery patients receiving dual modality prophylaxis. J Thromb Thrombolysis. 2011 Aug; 32(2):209-14. PMID: 21505787.
      Citations:    
    82. Hirani A, Cavallazzi R, Vasu T, Pachinburavan M, Kraft WK, Leiby B, Short W, Desimone J, Squires KE, Weibel S, Kane GC. Prevalence of obstructive lung disease in HIV population: a cross sectional study. Respir Med. 2011 Nov; 105(11):1655-61. PMID: 21703841.
      Citations:    
    83. Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, De Lepeleire I, Radziszewski W, Wagner JA, Lai E. The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets. 2011; 22(7):495-503. PMID: 21526889.
      Citations:    
    84. Galanis T, Kraft WK, Merli GJ. Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient. Adv Surg. 2011; 45:361-90. PMID: 21954699.
      Citations:    
    85. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction. 2011 Mar; 106(3):574-80. PMID: 20925688.
      Citations:    
    86. Vasu TS, Doghramji K, Cavallazzi R, Grewal R, Hirani A, Leiby B, Markov D, Reiter D, Kraft WK, Witkowski T. Obstructive sleep apnea syndrome and postoperative complications: clinical use of the STOP-BANG questionnaire. Arch Otolaryngol Head Neck Surg. 2010 Oct; 136(10):1020-4. PMID: 20956751.
      Citations:    
    87. Colon-Gonzalez F, Kraft WK. Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol. 2010 Oct; 6(10):1277-86. PMID: 20795794.
      Citations:    
    88. Stoch SA, Gargano C, Valentine J, Braun MP, Murphy MG, Fedgchin M, Majumdar A, Pequignot E, Gottesdiener KM, Petty KJ, Panebianco D, Dean D, Kraft WK, Greenberg HE. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemother Pharmacol. 2011 Jun; 67(6):1313-21. PMID: 20734049.
      Citations:    
    89. Lai E, Schwartz JI, Dallob A, Jumes P, Liu F, Kraft WK, Royalty J, Chodakewitz JA, McCrary Sisk C, Radziszewski W, Wagner JA. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets. 2010; 21(3):191-8. PMID: 20163197.
      Citations:    
    90. Waldman SA, Kraft WK, Nelson TJ, Terzic A. Experimental therapeutics: a paradigm for personalized medicine. Clin Transl Sci. 2009 Dec; 2(6):436-8. PMID: 20443936.
      Citations:    
    91. Waldman SA, Kraft WK, Nelson TJ, Terzic A. Clinical pharmacology: a paradigm for individualized medicine. Biomark Med. 2009 Dec; 3(6):679-84. PMID: 20477706.
      Citations:    
    92. Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009 May; 2(3):295-314. PMID: 21822447.
      Citations:    
    93. Kim DH, Daskalakis C, Whellan DJ, Whitman IR, Hohmann S, Medvedev S, Kraft WK. Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting. Am J Cardiol. 2009 May 15; 103(10):1391-5. PMID: 19427434.
      Citations:    
    94. Loboda A, Kraft WK, Fine B, Joseph J, Nebozhyn M, Zhang C, He Y, Yang X, Wright C, Morris M, Chalikonda I, Ferguson M, Emilsson V, Leonardson A, Lamb J, Dai H, Schadt E, Greenberg HE, Lum PY. Diurnal variation of the human adipose transcriptome and the link to metabolic disease. BMC Med Genomics. 2009 Feb 09; 2:7. PMID: 19203388.
      Citations:    
    95. Varki R, Pequignot E, Leavitt MC, Ferber A, Kraft WK. A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009 Jan 28; 9:2. PMID: 19175929.
      Citations:    
    96. Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, Moody DE, Kaltenbach K, Ehrlich ME. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008 Sep; 122(3):e601-7. PMID: 18694901.
      Citations:    
    97. Kraft WK, Waldman SA. Bridging the therapeutic continuum of drug development, regulation and use. Expert Rev Clin Pharmacol. 2008 Jan; 1(1):1-3. PMID: 24410503.
      Citations:    
    98. Larusso J, Waldman SA, Kraft WK. Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery. Expert Rev Clin Pharmacol. 2008 Jan; 1(1):27-37. PMID: 24410507.
      Citations:    
    99. Kraft WK, Waldman SA. Expert Review in Clinical Pharmacology. Bridging the Therapeutic Continuum of Drug Development, Regulation and Use. 2008; 1(1):1-3. View Publication.
    100. LaRusso J, Waldman SA, Kraft WK. Expert Review in Clinical Pharmacology. Aprepitant For The Prevention Of Nausea And Vomiting Associated With Chemotherapy And Postoperative Recovery. 2008; 1(1):27-37.
    101. Majumdar AK, Yan KX, Selverian DV, Barlas S, Constanzer M, Dru J, McCrea JB, Ahmed T, Frick GS, Kraft WK, Petty KJ, Greenberg HE. Effect of aprepitant on the pharmacokinetics of intravenous midazolam. J Clin Pharmacol. 2007 Jun; 47(6):744-50. PMID: 17463213.
      Citations:    
    102. Gong L, Greenberg HE, Perhach JL, Waldman SA, Kraft WK. The pharmacokinetics of taurolidine metabolites in healthy volunteers. J Clin Pharmacol. 2007 Jun; 47(6):697-703. PMID: 17395893.
      Citations:    
    103. Ghanim AJ, Daskalakis C, Eschelman DJ, Kraft WK. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007 Dec; 24(3):247-54. PMID: 17385008.
      Citations:    
    104. Patel TB, Pequignot E, Parker SH, Leavitt MC, Greenberg HE, Kraft WK. Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study. Int J Clin Pharmacol Ther. 2007 Mar; 45(3):161-8. PMID: 17416111.
      Citations:    
    105. Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Kosoglou T, Greenberg HE, Kraft WK, Frick G, Murphy G, Gottesdiener K, Paolini JF. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J Clin Pharmacol. 2006 Mar; 46(3):321-7. PMID: 16490808.
      Citations:    
    106. Kakhniashvili I, Filicko J, Kraft WK, Flomenberg N. Heterogeneous clearance of antithymocyte globulin after CD34+-selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005 Aug; 11(8):609-18. PMID: 16041311.
      Citations:    
    107. Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother. 2004 Nov; 48(11):4306-14. PMID: 15504857.
      Citations:    
    108. Agrawal NG, Matthews CZ, Mazenko RS, Woolf EJ, Porras AG, Chen X, Miller JL, Michiels N, Wehling M, Schultz A, Gottlieb AB, Kraft WK, Greenberg HE, Waldman SA, Curtis SP, Gottesdiener KM. The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. J Clin Pharmacol. 2004 Oct; 44(10):1125-31. PMID: 15342613.
      Citations:    
    109. Kraft WK, Waldman SA, Weinberg D, Laine C. Thomas Jefferson University K30 Program Externship: Critical Review of the Medical Literature at The Annals Of Internal Medicine. Clinical Research Perspective. 2004; (1).
    110. Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, Kusma SE, Deutsch PJ, Greenberg HE, Waldman SA. Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol. 2004 Mar; 44(3):305-13. PMID: 14973305.
      Citations:    
    111. Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, Waldman SA. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol. 2004 Jan; 44(1):67-72. PMID: 14681343.
      Citations:    
    112. Burke J, Kraft WK, Greenberg HE, Gleave M, Pitari GM, VanBuren S, Wagner JA, Waldman SA. Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation. J Clin Pharmacol. 2003 Sep; 43(9):983-9. PMID: 12971030.
      Citations:    
    113. Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther. 2003 May; 25(5):1407-19. PMID: 12867217.
      Citations:    
    114. Hastie AT, Kraft WK, Nyce KB, Zangrilli JG, Musani AI, Fish JE, Peters SP. Asthmatic epithelial cell proliferation and stimulation of collagen production: human asthmatic epithelial cells stimulate collagen type III production by human lung myofibroblasts after segmental allergen challenge. Am J Respir Crit Care Med. 2002 Jan 15; 165(2):266-72. PMID: 11790666.
      Citations:    
    115. Kraft WK, Waldman SA. Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses? Drug Saf. 2001; 24(9):637-43. PMID: 11522118.
      Citations:    
    116. Kraft W, Steinberg M, Delnevo C. How to Help Your Patients Quit Smoking. IM: Internal Medicine. 1999.
    117. Kraft W, Greenberg HE, Waldman SA. Paradoxical hypotension and bradycardia after intravenous arginine vasopressin. J Clin Pharmacol. 1998 Mar; 38(3):283-6. PMID: 9549667.
      Citations:    
    118. Hartmann K, Kuffer M, Balzarini J, Naesens L, Goldberg M, Erfle V, Goebel FD, De Clercq E, Jindrich J, Holy A, Bischofberger N, Kraft W. Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Feb 01; 17(2):120-8. PMID: 9473012.
      Citations:    
    119. Block A, Hartmann K, Lutz H, Kraft W. [Placebo-controlled double-blind study on the efficacy of a paramunity inducer in the treatment of naturally FeLV-infected cats]. Tierarztl Prax. 1997 May; 25(3):261-6. PMID: 9289888.
      Citations:    
    120. Kraft W, Kuffer M. [Treatment of severe neutropenias in dogs and cats with filgrastim]. Tierarztl Prax. 1995 Dec; 23(6):609-13. PMID: 8585081.
      Citations:    
    121. Dodurka T, Kraft W. [Alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamate dehydrogenase (GLDH), alkaline phosphatase (AP) and gamma-glutamyltransferase (GGP) in intestinal diseases of dogs]. Berl Munch Tierarztl Wochenschr. 1995 Jul; 108(7):244-8. PMID: 8593145.
      Citations:    
    122. Vollmar AM, Preusser U, Gerbes AL, Kraft W, Schulz R. Endothelin concentration in plasma of healthy dogs and dogs with congestive heart failure, renal failure, diabetes mellitus, and hyperadrenocorticism. J Vet Intern Med. 1995 Mar-Apr; 9(2):105-11. PMID: 7760309.
      Citations:    
    123. Vollmar AM, Montag C, Preusser U, Kraft W, Schulz R. Atrial natriuretic peptide and plasma volume of dogs suffering from heart failure or dehydration. Zentralbl Veterinarmed A. 1994 Sep; 41(7):548-57. PMID: 8831270.
      Citations:    
    124. Kraft W. [Diagnosis of hemostasis disorders]. Tierarztl Prax. 1992 Aug; 20(4):355-7. PMID: 1412425.
      Citations:    
    125. Vollmar AM, Reusch C, Kraft W, Schulz R. Atrial natriuretic peptide concentration in dogs with congestive heart failure, chronic renal failure, and hyperadrenocorticism. Am J Vet Res. 1991 Nov; 52(11):1831-4. PMID: 1838467.
      Citations:    
    126. Kraft W, Lechner J, Vollmar AM, Reusch C, Warmbier M, Lohss E. [Indocyanine green test in the dog]. Tierarztl Prax. 1991 Aug; 19(4):439-46. PMID: 1948994.
      Citations:    
    127. Israel S, Kraft W. [Effect of sports on the distribution of body fat]. Z Gesamte Inn Med. 1990 Dec 15; 45(24):729-32. PMID: 2102031.
      Citations:    
    128. Kraft W, Ghermai AK, von Bomhard D. [Two cases of colitis cystica profunda in dogs]. Tierarztl Prax. 1989; 17(3):299-302. PMID: 2573171.
      Citations:    
    129. Morgan D, Kraft W, Bender M, Pearson A. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities. Gastroenterology. 1988 Nov; 95(5):1178-84. PMID: 3049213.
      Citations:    
    130. Scharmann W, Kraft W. [Inhibition of blood coagulation in vitro by protease of Pseudomonas aeruginosa]. Blut. 1974 Feb; 28(2):90-9. PMID: 4272950.
      Citations:    
    Kraft's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (600)
    Explore
    _
    Co-Authors (80)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _